A rare but serious complication of ticagrelor therapy: a case report

European Heart Journal. Case Reports
Manfredi AriotiNicoletta Bianca De Cesare

Abstract

Ticagrelor is a widely used P2Y12 inhibitor and represents a fundamental therapeutic agent in acute coronary syndrome treatment and selected post-percutaneous coronary intervention (PCI) cases. Dyspnoea and bradycardia are the most common side effects but the latter has been reported to be of trivial clinical significance. A 51-year-old gentleman underwent PCI to left anterior descending and obtuse marginal for unstable angina receiving a loading dose of ticagrelor (180 mg). During hospital stay, whilst on telemetry monitoring, a 16 s long, symptomatic, asystolic ventricular standstill was recorded prompting ticagrelor interruption and a switch to prasugrel. Despite ventricular pauses have been reported in dedicated analyses of Phase III trials, no apparent clinical consequences were documented. However, several reports have shown that significant brady-arrhythmic events might be linked to ticagrelor administration presenting both as sino-atrial and atrio-ventricular conduction disturbances. We report a case of asystole occurring 36 h after the administration of a loading dose.

References

Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Apr 29, 2014·Journal of the American College of Cardiology·Marco CattaneoSven Nylander
Aug 29, 2014·Pharmacotherapy·Paul P Dobesh, Julie H Oestreich
Jan 17, 2015·International Journal of Cardiology·Alexander GoldbergMajdi Halabi
Nov 10, 2015·International Journal of Cardiology·Alexander GoldbergMajdi Halabi
Dec 20, 2017·Annals of Internal Medicine·Sabina RossetPatrizio Pascale

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Related Papers

Acta Cardiologica
Raphaëlle-Ashley GuerbaaiPierre-Vladimir Ennezat
Expert Opinion on Pharmacotherapy
Paul A GurbelUdaya S Tantry
Future Cardiology
Jolanta M Siller-Matula, Bernd Jilma
Therapeutics and Clinical Risk Management
James J Nawarskas, Stanley S Snowden
© 2021 Meta ULC. All rights reserved